Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC ...

Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Corcept Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. HC ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Cryptocurrency company Coinbase Global (NASDAQ:COIN) could highlight record profitability and user metrics when the company ...

H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

CEO Dikla Czaczkes Akselbrad highlighted the recommendation by the independent Data Safety Monitoring Board (DSMB) to conclude the SHIELD II Phase 3 trial for D-PLEX100 upon the enrollment of 800 ...